Aytu BioPharma (NASDAQ:AYTU) Releases Quarterly Earnings Results, Beats Estimates By $0.24 EPS

Aytu BioPharma (NASDAQ:AYTU) announced its earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.24, Zacks reports. Aytu BioPharma had a negative return on equity of 63.03% and a negative net margin of 24.76%.The firm had revenue of $16.11 million for the quarter, compared to analysts’ expectations of $12.28 million.

Here are the key takeaways from Aytu BioPharma’s conference call:

• EXXUA revenue rose to $3.9 million in fiscal Q4 from $2.4 million in Q3, while prescriptions increased to 3,323 for the quarter and reached a weekly record of nearly 400 in early September. Management highlighted broad prescribing across territories, growing refills, favorable payer approval rates, and encouraging physician feedback.
• EXXUA’s commercial rollout has involved significant sales-force turnover and a lengthy ramp period. The field team fell from 43 representatives in March to 32 in July before recovering to approximately 42, and management said new representatives may require six to nine months to become fully productive.
• Aytu returned to positive adjusted EBITDA of $0.5 million in Q4, generated $3.3 million of operating cash flow for fiscal 2026, repaid its revolver after year-end, and reduced interest expense through debt paydown. Cash was relatively stable at $26.3 million at fiscal year-end despite continued deleveraging.
• Fiscal 2027 will include increased EXXUA investment, with cash-based operating expenses expected at $45 million to $49 million and up to $6 million allocated to sales, marketing, and education. Management expects weaker adjusted EBITDA and cash flow in the first half because of launch spending and ADHD seasonality, but forecasts positive adjusted EBITDA over the six months ending June 2027 and consolidated gross margins approaching 66%–67% in Q4.
• The ADHD portfolio generated $10.4 million of Q4 revenue, up sequentially, while Adzenys and its authorized generic retained about 80% of prescriptions in their market. Cotempla’s authorized generic is gaining prescriptions, and Teva has not yet launched its competing generic, creating potential upside to management’s assumptions.

Aytu BioPharma Stock Performance

Shares of AYTU stock opened at $2.28 on Thursday. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. The company has a market cap of $24.46 million, a PE ratio of -1.37 and a beta of 0.26. The company’s fifty day simple moving average is $2.22 and its 200-day simple moving average is $2.33. Aytu BioPharma has a 52 week low of $1.65 and a 52 week high of $3.07.

Key Stories Impacting Aytu BioPharma

Here are the key news stories impacting Aytu BioPharma this week:

• Positive Sentiment: Quarterly results exceeded expectations. Aytu reported fourth-quarter revenue of $16.1 million, up 6.4% year over year and approximately 31% above the cited analyst estimate of $12.28 million. The company’s loss of $0.05 per share was also narrower than the consensus loss estimate of $0.22-$0.29. Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
• Positive Sentiment: EXXUA launch is gaining momentum. The recently launched treatment generated $3.9 million in fourth-quarter revenue and $6.6 million for fiscal 2026. Fourth-quarter prescriptions reached 3,323, approximately 138% higher than the prior quarter, making EXXUA the main growth driver. Aytu BioPharma Q4 2026 Earnings Call Highlights
• Positive Sentiment: Profitability indicators improved. Aytu posted fourth-quarter adjusted EBITDA of $0.5 million, while ending June with $26.3 million in cash. Management’s growth outlook also includes a target of 66%-67% gross margin by the fourth quarter of fiscal 2027. Aytu FY2027 Operating Expense Plan
• Neutral Sentiment: Aytu is a specialty pharmaceutical company focused on central nervous system medicines, with revenue from EXXUA and its ADHD portfolio. Management plans $49 million-$54 million of fiscal 2027 operating expenses to support commercialization and growth.
• Negative Sentiment: The company remains loss-making. Despite beating estimates, Aytu reported negative net margins and return on equity, and analysts continue to forecast a full-year loss. The planned increase in operating spending could pressure cash flow if EXXUA sales growth does not continue.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on AYTU shares. Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Citigroup restated a “positive” rating on shares of Aytu BioPharma in a report on Tuesday. Ascendiant Capital Markets upped their target price on Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research note on Thursday, June 11th. Finally, Weiss Ratings raised Aytu BioPharma from a “sell (d-)” rating to a “sell (d)” rating in a research note on Tuesday. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.75.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.